SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syschem (India) - Quaterly Results

06 May 2024 Evaluate
A decent increase of about 54.64% in the turnover to Rs. 880.02 millions was observed for the quarter ended March 2024. The turnover stood at Rs. 569.09 millions during the similar quarter previous year.The Net Loss for the quarter ended March 2024 is Rs. -2.64 millions as compared to Net Profit of Rs. 3.88 millions of corresponding quarter ended March 2023A decline of 17.69 millions was observed in the OP in the quarter ended March 2024 from 26.18 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 880.02 569.09 54.64 2334.77 1303.77 79.08 2334.77 1303.77 79.08
Other Income 1.51 0.99 52.53 1.70 2.48 -31.45 1.70 2.48 -31.45
PBIDT 17.69 26.18 -32.43 71.54 88.96 -19.58 71.54 88.96 -19.58
Interest 0.11 0.00 0.00 2.53 0.42 502.38 2.53 0.42 502.38
PBDT 17.58 26.18 -32.85 69.01 88.54 -22.06 69.01 88.54 -22.06
Depreciation 6.70 5.92 13.18 27.89 27.03 3.18 27.89 27.03 3.18
PBT 10.88 20.26 -46.30 41.12 61.51 -33.15 41.12 61.51 -33.15
TAX 13.52 16.38 -17.46 13.52 16.38 -17.46 13.52 16.38 -17.46
Deferred Tax 13.52 16.38 -17.46 13.52 16.38 -17.46 13.52 16.38 -17.46
PAT -2.64 3.88 -168.04 27.60 45.13 -38.84 27.60 45.13 -38.84
Equity 398.63 318.90 25.00 398.63 318.90 25.00 398.63 318.90 25.00
PBIDTM(%) 2.01 4.60 -56.30 3.06 6.82 -55.09 3.06 6.82 -55.09

Syschem (India) Share Price

52.98 0.85 (1.63%)
17-Apr-2026 10:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1689.10
Dr. Reddys Lab 1221.40
Cipla 1239.90
Zydus Lifesciences 946.80
Lupin 2333.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×